EPTIS – Database of Proficiency Testing Schemes

EPTIS

Page 1 of 2 (Hits 1 to 20 of 21)

ID

Country

PT provider

PT scheme

Last changed

690909

Argentina

ILT - Interlaboratory Test S.A.

ILT-U-2072 - Respiratory protective devices (relevant to SARS-CoV-2 virus / COVID-19 disease)

2020-06-09

PT name

(ILT-U-2072 - Respiratory protective devices (relevant to SARS-CoV-2 virus / COVID-19 disease))

690914

Argentina

ILT - Interlaboratory Test S.A.

Face mask (relevant to SARS-CoV-2 virus / COVID-19 disease) - ILT-U-2091 / ILT-U-2097 / ILT-U-2100 / ILT-U-2112

2020-09-16

PT name

(Face mask (relevant to SARS-CoV-2 virus / COVID-19 disease) - ILT-U-2091 / ILT-U-2097 / ILT-U-2100 / ILT-U-2112)

794057

Australia

RCPAQAP

PHLN: SARS-CoV-2 and other coronaviruses

2020-10-23

PT name	(PHLN: SARS-CoV-2 and other coronaviruses)
Remarks	(laboratory testing platforms that are utilised in the whole genome sequencing of SARS-CoV-2. Available) (free of charge to Australian public health laboratories that require the capability to test for SARS-CoV-2.)
Test item	(Inactivated virus for Whole genome sequencing)
Tested property	(Diluted SARS-CoV-2 (inactivated)) (Diluted SARS-CoV-2 (inactivated))

880833

Brazil

ControlLab Controle de Qualidade para Laboratórios Ltda

Clinical PT - Molecular panel of Respiratory Infections and Pneumonia [EP Clínico - Painel Molecular para Infecções Respiratórias e Pneumonias]

2023-05-29

Tested property

(Coronavírus (SARS-CoV-2)) (Respiratory Syncytial Virus) (Respiratory Syncytial Virus A) (Respiratory Syncytial Virus B)

1009007

Brazil

ControlLab Controle de Qualidade para Laboratórios Ltda

Clinical PT - Molecular Biology - Coronavirus (SARS-CoV2): saliva [EP Clínico - Biologia Molecular Coronavírus (SARS-CoV2): saliva]

2023-01-31

PT name	(Clinical PT - Molecular Biology - Coronavirus (SARS-CoV2): saliva)
Scheme name in national language	(EP Clínico - Biologia Molecular Coronavírus (SARS-CoV2): saliva)
Test item	(lyophilized cell suspension or lyophilized human saliva (virus inactivated))
Tested property	(Molecular Biology - Coronavirus (SARS-CoV2): saliva)

947164

Brazil

ControlLab Controle de Qualidade para Laboratórios Ltda

Clinical PT - Coronavirus (SARS-CoV2): antigen research by automation [EP Clínico - Coronavírus (SARS-CoV2): pesquisa de antígeno por automação]

2022-07-26

PT name	(Clinical PT - Coronavirus (SARS-CoV2): antigen research by automation)
Scheme name in national language	(EP Clínico - Coronavírus (SARS-CoV2): pesquisa de antígeno por automação)
Test item	(Lyophilized cell suspension (inactivated virus))
Tested property	(Coronavirus (SARS-CoV2): antigen research by automation)

1347466

Brazil

ControlLab Controle de Qualidade para Laboratórios Ltda

Clinical PT - POCT Respiratory Infections Panel [EP Clínico - POCT Painel para Infecções Respiratórias]

2025-03-24

Tested property

(Coronavirus (SARS-CoV2): nasopharynx and oropharynx) (Respiratory Syncytial Virus (RSV))

1163321

Germany

INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories

Virus Genome Detection – Respiratory Virus Panel 2 for Multiplex Tests (432) [Virusgenom-Nachweis - Respiratorisches Virus-Panel 2 für Multiplex Teste (432)]

2024-04-16

PT name	(Virus Genome Detection – Respiratory Virus Panel 2 for Multiplex Tests (432))
Remarks	(with currently circulating virus variants. Some of the samples can contain chemically inactivated) (avian influenza A viruses. Note for laboratories from non-EU countries: The shipment of sample) (INSTAND EQA schemes for the corresponding viruses. The interdisciplinary, non-profit, scientific)
Scheme name in national language	(Virusgenom-Nachweis - Respiratorisches Virus-Panel 2 für Multiplex Teste (432))
Tested property	(influenza A and B viruses incl. avian influenza A viruses, respiratory syncytial viruses (groups A and B) and SARS-CoV-2 (inactivated))

1163304

Germany

INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories

Virus Genome Detection – Respiratory Virus Panel 1 for Multiplex Tests (431) [Virusgenom-Nachweis - Respiratorisches Virus-Panel 1 für Multiplex Teste (431)]

2024-04-16

PT name	(Virus Genome Detection – Respiratory Virus Panel 1 for Multiplex Tests (431))
Remarks	(currently circulating virus variants. Some of the samples can contain chemically inactivated avian) (influenza A viruses. Note for laboratories from non-EU countries: The shipment of sample materials) (, we refer to the INSTAND EQA schemes for the corresponding viruses. The interdisciplinary, non)
Scheme name in national language	(Virusgenom-Nachweis - Respiratorisches Virus-Panel 1 für Multiplex Teste (431))
Tested property	(incl. avian influenza A viruses, parecho, parainfluenza, respiratory syncytial viruses (groups A and B) and SARS-CoV-2 (inactivated), respectively) (respiratory adeno, boca, corona, entero, human metapneumo, human rhino, influenza A and B viruses)

1163345

Germany

INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories

Virus Genome Detection – SARS-CoV-2 sequence analysis (417) [Virusgenom-Nachweis - SARS-CoV-2 Sequenzanalyse (417)]

2024-04-16

PT name	(Virus Genome Detection – SARS-CoV-2 sequence analysis (417))
Remarks	(Please note: Starting in 2024, only results of SARS-CoV-2 sequence analyses for SARS-CoV-2)
Scheme name in national language	(Virusgenom-Nachweis - SARS-CoV-2 Sequenzanalyse (417))
Tested property	(Differentiation of SARS-CoV-2 variants with clinical relevance using whole genome sequencing)

1163338

Germany

INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories

Virus Genome Detection – SARS-CoV-2 (409) [Virusgenom-Nachweis - SARS-CoV-2 (409)]

2024-04-16

PT name	(Virus Genome Detection – SARS-CoV-2 (409))
Scheme name in national language	(Virusgenom-Nachweis - SARS-CoV-2 (409))
Tested property	(The sample set contains defined samples with SARS-CoV-2 (full virus, inactivated) and, if necessary) (Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for SARS-CoV-2)

1160040

Germany

INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories

Virus Antigen Detection – SARS-CoV-2 (Ag) (410) [Virusantigen-Nachweis - SARS-CoV-2 (Ag) (410)]

2024-04-16

PT name	(Virus Antigen Detection – SARS-CoV-2 (Ag) (410))
Remarks	(samples with antigen from SARS-CoV-2 (inactivated) and, if necessary, samples with antigen from human) (immunoassays for the detection of SARS-CoV-2 antigen. The interdisciplinary, non-profit)
Scheme name in national language	(Virusantigen-Nachweis - SARS-CoV-2 (Ag) (410))
Tested property	(SARS-CoV-2 antigen)

1169419

Germany

INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories

Virus Immunology – SARS-CoV-2 (Ab) (416) [Virusimmunologie - SARS-CoV-2 (Ak) (416)]

2024-05-14

PT name	(Virus Immunology – SARS-CoV-2 (Ab) (416))
Scheme name in national language	(Virusimmunologie - SARS-CoV-2 (Ak) (416))
Tested property	(Anti-SARS-CoV-2 total (without differentiation of IgG, IgA and IgM)) (Anti-SARS-CoV-2 IgG) (Anti-SARS-CoV-2 IgG avidity) (Anti-SARS-CoV-2 IgA) (Anti-SARS-CoV-2 IgM (not certified))

437169

Germany

INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories

Virus Genome Detection – Coronaviruses incl. SARS-CoV-2 (340) [Virusgenom-Nachweis – Coronaviren inkl. SARS-CoV-2 (340)]

2024-04-16

PT name	(Virus Genome Detection – Coronaviruses incl. SARS-CoV-2 (340))
Scheme name in national language	(Virusgenom-Nachweis – Coronaviren inkl. SARS-CoV-2 (340))
Tested property	(Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for SARS-CoV) (Option for differentiaton between SARS-CoV-2, MERS-CoV and other human coronaviruses (samples which) (contain SARS-CoV-2 and MERS-CoV, repectively, are inactivated)

1271562

Hungary

QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd.

Virus serology: SARS-CoV-2 [Vírus szerológia: SARS-CoV-2]

2024-10-08

PT name	(Virus serology: SARS-CoV-2)
Remarks	(The content of the scheme: SARS-CoV-2 antibody (IgG-, IgG-S, IgG-N, IgM, IgA, total antibody)
Scheme name in national language	(Vírus szerológia: SARS-CoV-2)
Tested property	(Anti-SARS-CoV-2 total (OD, S/CO, quantitative, evaluation)) (Anti-SARS-CoV-2 – IgG-S (OD, S/CO, quantitative, evaluation)) (Anti-SARS-CoV-2 – IgG-N (OD, S/CO, quantitative, evaluation)) (Anti-SARS-CoV-2 – IgG (OD, S/CO, quantitative, evaluation)) (Anti-SARS-CoV-2 – IgM (OD, S/CO, quantitative, evaluation))

1271426

Hungary

QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd.

Virus nucleic acid determination: SARS-CoV-2 [Vírus nukleinsav meghatározás: SARS-CoV-2]

2024-11-25

PT name	(Virus nucleic acid determination: SARS-CoV-2)
Remarks	(amplification techniques (NAT) for qualitative determination of SARS-CoV-2 virus. Qualitative results are)
Scheme name in national language	(Vírus nukleinsav meghatározás: SARS-CoV-2)

706310

Portugal

Programa Nacional de Avaliação Externa da Qualidade (PNAEQ) INSA DEP UAEQ

SARS-CoV-2, molecular detection [SARS-CoV-2, molecular detection]

2024-03-13

PT name	(SARS-CoV-2, molecular detection)
Scheme name in national language	(SARS-CoV-2, molecular detection)
Tested property	(SARS-CoV-2 virus)

134427

United Kingdom

LGC AXIO Proficiency Testing

Water Microbiology Scheme - (QWAS)

2021-03-01

Tested property	(SARS-CoV-2) (Detection of SARS-CoV-2) (Optional quantification of SARS-CoV-2 (Trial))
Testing method	(2 x 1.5 ml vial (A & B) of non-infectious, SARS-CoV-2 virus (whole genome) 1 x >100ml sterile water diluent 1 x >20g sterile sludge matrix) (0 to 10000 virus copies per ml)

769005

United Kingdom

LGC AXIO Proficiency Testing

SARS-CoV-2 Proficiency Testing Scheme

2022-05-04

PT name	(SARS-CoV-2 Proficiency Testing Scheme)
Test item	(SARS-CoV-2 (Serological)- 3 x 0.75 ml samples for detection for the SARS-CoV-2 antibodies -NEW 2020) (SARS-CoV-2 (Molecular)- 2 x 1.5ml samples for SARS-CoV-2 virus -NEW 2020) (SARS-CoV-2 antigen - 3 x swab based samples (A, B, and C). Non-infectious simulated patient) (nasopharyngeal samples containing the SARS-CoV-2 nucleocapsid protein.) (SARS-CoV-2 (Molecular)- 2 x swab based samples. Non-infectious simulated nasopharyngeal samples)
Tested property	(SARS-CoV-2 IgA, IgG, IgM, Total antibodies) (SARS-CoV-2 virus) (SARS-CoV-2 virus) (SARS-CoV-2 virus - The samples contain the whole genome) (SARS-CoV-2 virus - The samples contain the whole genome)

1144039

United Kingdom

Weqas

POCT Respiratory Virus [POCT Respiratory Virus]

2024-10-01

PT name	(POCT Respiratory Virus)
Remarks	(targeted for Influenza A (and subtypes) Influenza B, SARS-Cov-2, and Respiratory Syncytial Virus) (), influenza B, RSV, SARS-Cov-2 or no virus. A range of differing viral loads are distributed including) (virus in a stabilising buffer which may contain Influenza A (either / both H1N1 and H3N2 subtypes) (the laboratory / POCT site to correctly identify the virus (es) present in the sample, the) (sensitivities of the methods / devices, are also considered. A correct identification of the virus (es) is)
Scheme name in national language	(POCT Respiratory Virus)
Test item	(Buffered material spiked with inactivated virus)
Tested property	(SARS-CoV-2 Ag (RNA))

Page 1 of 2 (Hits 1 to 20 of 21)